These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36052089)

  • 1. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression.
    Gomes YCP; Freitas NL; Souza FS; Sandim V; Pereira DA; Nogueira FCS; Echevarria-Lima J; Leite ACCB; Lima MASD; Silva MTT; Araújo AQC; Vicente ACP; Espíndola OM
    Front Immunol; 2022; 13():949516. PubMed ID: 36052089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.
    Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM
    Front Immunol; 2021; 12():737941. PubMed ID: 34764955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from the Cerebrospinal Fluid Analysis of HTLV-1-Infected Individuals: Biomarkers of Inflammation for HAM/TSP Development.
    Freitas NL; Gomes YCP; Souza FDS; Torres RC; Echevarria-Lima J; Leite ACCB; Lima MASD; Araújo AQC; Silva MTT; Espíndola OM
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.
    Takatani M; Crispim ME; Fraiji N; Stefani MM; Kiesslich D
    Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e5. PubMed ID: 28380116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers.
    Yamauchi J; Araya N; Yagishita N; Sato T; Yamano Y
    Pharmacol Ther; 2021 Feb; 218():107669. PubMed ID: 32835825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.
    Sato T; Yagishita N; Tamaki K; Inoue E; Hasegawa D; Nagasaka M; Suzuki H; Araya N; Coler-Reilly A; Hasegawa Y; Tsuboi Y; Takata A; Yamano Y
    Front Microbiol; 2018; 9():1651. PubMed ID: 30090093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Sato T; Coler-Reilly A; Utsunomiya A; Araya N; Yagishita N; Ando H; Yamauchi J; Inoue E; Ueno T; Hasegawa Y; Nishioka K; Nakajima T; Jacobson S; Izumo S; Yamano Y
    PLoS Negl Trop Dis; 2013; 7(10):e2479. PubMed ID: 24130912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.
    Guerreiro JB; Santos SB; Morgan DJ; Porto AF; Muniz AL; Ho JL; Teixeira AL; Teixeira MM; Carvalho EM
    Clin Exp Immunol; 2006 Aug; 145(2):296-301. PubMed ID: 16879249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Saito M; Tanaka R; Arishima S; Matsuzaki T; Ishihara S; Tokashiki T; Ohya Y; Takashima H; Umehara F; Izumo S; Tanaka Y
    Retrovirology; 2013 May; 10():51. PubMed ID: 23651542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Enose-Akahata Y; Jacobson S
    Retrovirology; 2019 Nov; 16(1):35. PubMed ID: 31783764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study.
    de Oliveira CJV; Neto JAC; Liberato de Matos SNF; Oliveira P; Tannus M; Castro N; Rocha PN; Carvalho EM
    J Sex Med; 2023 Feb; 20(3):269-276. PubMed ID: 36751985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression.
    Matsuura E; Nozuma S; Tashiro Y; Kubota R; Izumo S; Takashima H
    J Neurol Sci; 2016 Dec; 371():112-116. PubMed ID: 27871430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
    Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y
    Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
    Gessain A; Mahieux R
    Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
    Tamaki K; Sato T; Tsugawa J; Fujioka S; Yagishita N; Araya N; Yamauchi J; Coler-Reilly ALG; Nagasaka M; Hasegawa Y; Yamano Y; Tsuboi Y
    Front Microbiol; 2019; 10():2110. PubMed ID: 31572323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial clusters of HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Nozuma S; Matsuura E; Matsuzaki T; Watanabe O; Kubota R; Izumo S; Takashima H
    PLoS One; 2014; 9(5):e86144. PubMed ID: 24802839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.
    Casseb J; de Oliveira AC; Vergara MP; Montanheiro P; Bonasser F; Meilman Ferreira C; Smid J; Duarte AJ
    J Med Virol; 2008 Mar; 80(3):392-8. PubMed ID: 18205234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP.
    Santana BB; Queiroz MAF; Cerveira RA; Rodrigues CM; da Silva Graça Amoras E; da Costa CA; de Sousa MS; Ishak R; Goulart LR; Vallinoto ACR
    BMC Infect Dis; 2021 Feb; 21(1):219. PubMed ID: 33632146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis.
    Tarokhian H; Taghadosi M; Rafatpanah H; Rajaei T; Azarpazhooh MR; Valizadeh N; Rezaee SAR
    Virus Res; 2017 Jan; 228():1-6. PubMed ID: 27845163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma.
    Giusti RM; Maloney EM; Hanchard B; Morgan OS; Steinberg SM; Wachter H; Williams E; Cranston B; Fuchs D; Manns A
    Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):699-704. PubMed ID: 8877061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.